Scope
Selected recommendations from WHO’s 2026 second edition of consolidated TB treatment and care guidance. The update stratifies short-regimen choices for pulmonary pre-XDR-TB by severity and adds palliative care alongside effective treatment. Drug-susceptible, paediatric, drug-resistant and supportive-care decisions retain their distinct eligibility criteria.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Drug-susceptible pulmonary TB
- Treat new drug-susceptible pulmonary TB with six months of rifampicin-containing therapy: two months of isoniazid, rifampicin, pyrazinamide and ethambutol, then four months of isoniazid and rifampicin. Use daily dosing throughout; thrice-weekly dosing is not recommended. [1]
- Prefer fixed-dose combinations over separate formulations when treating drug-susceptible TB, a conditional recommendation. A positive sputum smear at the end of the intensive phase alone is not a reason to extend that phase in a new patient receiving rifampicin throughout treatment. [1]
- For drug-susceptible pulmonary TB from age 12, a conditional four-month option is two months of isoniazid, rifapentine, moxifloxacin and pyrazinamide followed by two months of isoniazid, rifapentine and moxifloxacin (2HPMZ/2HPM). Do not apply this shorter option outside research to people under 40 kg, pregnancy/breastfeeding/postpartum groups, HIV with CD4 below 100 cells/mm³, or the excluded extrapulmonary forms. [1]
Children and extrapulmonary disease
- Use a four-month 2HRZ(E)/2HR regimen for children and adolescents between three months and 16 years with non-severe TB and no suspicion or evidence of multidrug- or rifampicin-resistant disease. Ethambutol in the first two months is recommended where HIV or isoniazid resistance prevalence is high. [1]
- For the childhood short regimen, non-severe disease means peripheral lymph-node TB, intrathoracic nodes without airway obstruction, uncomplicated pleural effusion, or paucibacillary non-cavitary disease limited to one lobe without a miliary pattern. Children outside these criteria need standard six-month treatment or the appropriate severe extrapulmonary regimen. [1]
- Infants aged zero to three months with suspected or confirmed pulmonary TB or peripheral lymphadenitis need prompt six-month treatment, 2HRZ(E)/4HR. Any dose adjustment for age or toxicity should be made by a clinician experienced in paediatric TB. [1]
- Children with TB meningitis or osteoarticular TB should receive two months of HRZE followed by ten months of HR, totalling twelve months. For TB meningitis, use initial adjunctive dexamethasone or prednisolone tapered over six to eight weeks; adjunctive steroids in TB pericarditis are only conditionally recommended. [1]
Six-month pretomanid-containing drug-resistant regimens
- WHO conditionally suggests six-month bedaquiline–pretomanid–linezolid–moxifloxacin (BPaLM) instead of nine-month or longer regimens for eligible MDR/RR-TB. The evidence certainty is very low; suitability must be assessed before using the short regimen. [1]
- BPaL-based recommendations apply from age 14 and exclude pregnancy or breastfeeding. They include pulmonary and selected extrapulmonary TB, but exclude central nervous system, osteoarticular or disseminated multiorgan disease. Previous exposure of more than one month to component or relevant related medicines requires resistance to the exposed medicines to be excluded. [1]
- Obtain fluoroquinolone susceptibility testing without delaying BPaL-based treatment. If resistance is unknown, start BPaLM and adjust when results return; retain BPaLM when susceptible. For confirmed pulmonary pre-XDR-TB, the conditional recommendations favour BPaL for non-severe disease and BPaLC, adding clofazimine, for severe disease. [1]
- For these adult/adolescent pulmonary pre-XDR regimen decisions, severe disease means cavities with sputum smear at least 1+, or smear at least 2+ even without cavities, including equivalent recommended molecular-test results. Non-severe disease is disease not meeting this definition. [1]
Alternative short regimens and their limits
- WHO conditionally suggests a six-month bedaquiline–delamanid–linezolid–levofloxacin/clofazimine regimen for MDR/RR-TB. Eligibility includes all ages and pregnancy or breastfeeding, but excludes CNS, osteoarticular and disseminated multiorgan TB; previous component exposure requires the specified resistance assessment. [1]
- For the delamanid-based short regimen, obtain fluoroquinolone susceptibility results without delaying initiation. Start BDLLfxC while resistance is unknown; if susceptible, drop clofazimine and continue BDLLfx. For non-severe pulmonary pre-XDR-TB, stop levofloxacin and use BDLC. [1]
- Do not use the six-month BDLC regimen for severe pulmonary pre-XDR-TB under the conditional recommendation. Choose an eligible alternative, such as BPaLC or a longer regimen, with specialist assessment; severe disease in children younger than ten can include obstructing intrathoracic nodes or extensive lung disease and respiratory compromise without cavities. [1]
- Nine-month all-oral MDR/RR-TB regimens require fluoroquinolone resistance to be excluded. The conditional options BLMZ, BLLfxCZ and BDLLfxZ are preferred over longer regimens, with BLMZ preferred to BLLfxCZ and BLLfxCZ to BDLLfxZ; this is not interchangeable with the six-month regimen eligibility rules. [1]
Other resistance patterns, monitoring and coinfection
- For confirmed rifampicin-susceptible, isoniazid-resistant TB, use six months of rifampicin, ethambutol, pyrazinamide and levofloxacin, a conditional recommendation. Do not add streptomycin or other injectable drugs. [1]
- When a longer MDR/RR-TB regimen is required, construct it with at least four likely effective drugs initially using all three Group A agents and at least one Group B agent when possible. If only one or two Group A agents can be used, include both Group B agents; add Group C drugs if needed. Do not include kanamycin or capreomycin. [1]
- For patients on longer MDR/RR-TB regimens, monitor response with sputum culture as well as smear microscopy; monthly cultures are desirable. Treatment length is individualised according to response, with the guideline suggesting 18–20 months for most patients rather than automatic extension of every short regimen. [1]
- Under the drug-susceptible TB guidance, for HIV-associated TB without meningitis, start ART as soon as possible within two weeks of starting TB treatment regardless of CD4 count. TB meningitis is an exception: consider delaying ART four to eight weeks because immediate initiation is associated with more severe adverse events. [1]
- For MDR/RR-TB with hepatitis C coinfection, WHO conditionally suggests concurrent HCV and TB treatment rather than postponing HCV therapy until TB treatment has finished; the evidence certainty is very low. [1]
Adherence, community support and palliation
- Provide education and counselling about TB and adherence. Individualised support may combine material assistance, psychological support, tracing or digital reminders and staff education, rather than relying on medicine prescription alone. [1]
- Community or home-based treatment support is conditionally preferred to facility-based or unsupported treatment. Trained lay providers or health workers are preferred to unsupported treatment or family-only support; video support can replace in-person support when the technology and organisation are suitable. [1]
- For MDR-TB, mainly ambulatory and decentralised care are conditional recommendations. In high-burden settings, decentralised and family-centred integrated models may also support children and adolescents with TB symptoms or exposure. [1]
- The update conditionally recommends integrating trained-provider palliative assessment and interventions for pulmonary MDR/RR-TB alongside effective treatment. Address pain, distress and physical, psychological, social or spiritual needs; palliation complements rather than replaces effective TB therapy. [1]
Limitations and use
- This selected summary is not a complete prescribing protocol. Weight-based doses, interactions, toxicity monitoring, all short-regimen exclusions and adjustments require the full guideline and national TB programme.
- The updated drug-resistant short-regimen recommendations are conditional with very low-certainty evidence; eligibility and susceptibility results must guide specialist decisions.
- The six-month alternative childhood TB-meningitis regimen and complete longer-regimen construction tables are not reproduced. For HIV with drug-resistant TB, reconcile the dedicated ART section and current national HIV/TB guidance.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Tuberculosis: consolidated treatment and care guidance — second edition
Selected recommendation material consulted
Publication details
- Issuing organisation
- WHO
- First published
- 25 September 2026
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.